Therefore, the present study was designed to determine whether the combination of CNS therapy, using brain-specific VEGF overexpression, and systemic administration of CD provides greater functional benefits and/or enhances neuroprotection in NP-C. This evidence concerns the gene VEGFA and nasopharyngeal carcinoma.